Cannabidiol reduces lipopolysaccharide-induced vascular changes and inflammation in the mouse brain: An intravital microscopy study

Journal of Neuroinflammation

Volumn 8, Issue , 2011, Pages

  Ruiz Valdepeñas, Lourdes ^a   Martínez Orgado, José A ^a,b   Benito, Cristina ^a   Millán, África ^a,c   Tolón, Rosa M ^a   Romero, Julián ^a,c  

^a HOSPITAL UNIVERSITARIO FUNDACIÓN ALCORCÓN   (Spain)

^b HOSPITAL UNIVERSITARIO PUERTA DE HIERRO   (Spain)

^c UNIVERSIDAD FRANCISCO DE VITORIA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CYCLOOXYGENASE 2; INDUCIBLE NITRIC OXIDE SYNTHASE; LIPOPOLYSACCHARIDE; TUMOR NECROSIS FACTOR ALPHA; NOS2 PROTEIN, MOUSE; PTGS2 PROTEIN, MOUSE;

ADULT ANIMAL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CIRCULATION; CONTROLLED STUDY; DRUG EFFECT; ENCEPHALITIS; LEUKOCYTE; MICROSCOPY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SEPSIS; SINGLE DRUG DOSE; VASODILATATION; ANIMAL; BLOOD VESSEL; BRAIN; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; CYTOLOGY; GENETICS; INFLAMMATION; METABOLISM; METHODOLOGY; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; PIA MATER; VASCULARIZATION;

ANIMALS; BLOOD VESSELS; BLOOD-BRAIN BARRIER; BRAIN; CANNABIDIOL; CEREBROVASCULAR CIRCULATION; CYCLOOXYGENASE 2; INFLAMMATION; LEUKOCYTES; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED C57BL; MICROSCOPY; NITRIC OXIDE SYNTHASE TYPE II; OXIDATIVE STRESS; PIA MATER; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651456305     PISSN: None     EISSN: 17422094     Source Type: Journal    
DOI: 10.1186/1742-2094-8-5     Document Type: Article

References (43)

1. Annane D, Aegerter P, Jars-Guincestre MC, Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003, 168:165-172. 10.1164/rccm.2201087, 12851245.
2. Russel JA. Management of sepsis. New Eng J Med 2006, 355:1699-1713. 10.1056/NEJMra043632, 17050894.
3. Rosengarten B, Hecht M, Auch D, Ghofrani HA, Schermuly RT, Grimminger F, Kaps M. Microcirculatory dysfunction in the brain precedes changes in evoked potentials in endotoxin-induced sepsis syndrome in rats. Cerebrovasc Dis 2007, 23:140-147. 10.1159/000097051, 17124395.
4. Chisari M, Salomone S, Laureanti F, Copani A, Sortino MA. Modulation of cerebral vascular tone by activated glia: involvement of nitric oxide. J Neurochem 2004, 91:1171-1179. 10.1111/j.1471-4159.2004.02782.x, 15569260.
5. Czapski GA, Cakala M, Chalimoniuk M, Gajkowska B, Strosznajder JB. Role of nitric oxide in the brain during lipopolysaccharide-evoked systemic inflammation. J Neurosci Res 2007, 85:1694-703. 10.1002/jnr.21294, 17465018.
6. Rosengarten B, Hecht M, Wolff S, Kaps M. Autoregulative function in the brain in an endotoxic rat shock model. Inflamm Res 2008, 57:542-6. 10.1007/s00011-008-7199-2, 19109748.
7. Martínez-Orgado J, González R, Alonso MJ, Rodríguez-Martínez MA, Sánchez-Ferrer CF, Marín J. Endothelial factors and autoregulation during pressure changes in isolated newborn piglet cerebral arteries. Pediatr Res 1998, 44:161-167.
8. Mechoulam R, Peters M, Murillo-Rodriguez E, Hanus LO. Cannabidiol-recent advances. Chem Biodivers 2007, 4:1678-1692. 10.1002/cbdv.200790147, 17712814.
9. Fernandez-Ruiz JJ, Gonzalez S, Romero J, Ramos JA. Cannabinoids in neurodegeneration and neuroprotection. Cannabinoids as Therapeutics 2005, 79-109. Birkhäuser Verlag/Switzerland, Mechoulam R.
10. El-Remessy AB, Al-Shabrawey M, Khalifa Y, Tsai NT, Caldwell RB, Liou GI. Neuroprotective and blood-retinal barrier-preserving effects of cannabidiol in experimental diabetes. Am J Pathol 2006, 168:235-244. 10.2353/ajpath.2006.050500, 1592672, 16400026.
11. Alvarez FJ, Lafuente H, Rey-Santano MC, Mielgo VE, Gastiasoro E, Rueda M, Pertwee RG, Castillo AI, Romero J, Martínez-Orgado J. Neuroprotective effects of the nonpsychoactive cannabinoid cannabidiol in hypoxic-ischemic newborn piglets. Ped Res 2008, 64:653-658.
12. Pan H, Mukhopadhyay P, Rajesh M, Patel V, Mukhopadhyay B, Gao B, Haskó G, Pacher P. Cannabidiol attenuates cisplatin-induced nephrotoxicity by decreasing oxidative/nitrosative stress, inflammation, and cell death. J Pharmacol Exp Ther 2009, 328:708-714. 10.1124/jpet.108.147181, 2682269, 19074681.
13. Rajesh M, Mukhopadhyay P, Bátkai S, Patel V, Saito K, Matsumoto S, Kashiwaya Y, Horvath B, Mukhopadhyay B, Becker L, Haskó G, Liaudet L, Wink DA, Veves A, Mechoulam R, Pacher P. Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Col Cardiol 2010, 56:2115-2125.
14. Brian JE, Heistad DD, Faraci FM. Mechanisms of endotoxin-induced dilatation of cerebral arterioles. Am J Physiol 1995, 269:H783-H788.
15. Okamoto H, Ito O, Roman RJ, Hudetz AG. Role of Inducible Nitric Oxide Synthase and Cyclooxygenase-2 in Endotoxin-Induced Cerebral Hyperemia. Stroke 1998, 29:1209-1218.
16. Pytel P, Alexander J. Pathogenesis of septic encephalopathy. Curr Opin Neurol 2009, 22:283-287. 10.1097/WCO.0b013e32832b3101, 19387342.
17. Mempel TR, Scimone ML, Rodrigo Mora J, von Andrian UH. In vivo imaging of leukocyte trafficking in blood vessels and tissues. Curr Op Immunol 2004, 16:406-417.
18. Pertwee RG. The pharmacology and therapeutic potential of cannabidiol. Cannabinoids 2004, 32-83. Kluwer Academic Plenum Publishers, Di Marzo V.
19. Seylaz J, Charbonné R, Nanri K, Von Euw D, Borredon J, Kacem K, Méric P, Pinard E. Dynamic in vivo measurement of erythrocyte velocity and flow in capillaries and of microvessel diameter in the rat brain by confocal laser microscopy. J Cereb Blood Flow Metab 1999, 19:863-870. 10.1097/00004647-199908000-00005, 10458593.
20. Paul J, Strickland S, Melchor JP. Fibrin deposition accelerates neurovascular damage and neuroinflammation in mouse models of Alzheimer's disease. J Exp Med 2007, 204:1999-2008. 10.1084/jem.20070304, 2118680, 17664291.
21. Siami S, Annane D, Sharshar T. The encephalopathy in sepsis. Crit Care Clin 2008, 24:67-82. 10.1016/j.ccc.2007.10.001, 18241779.
22. Halin C, Rodrigo Mora J, Sumen C, von Andrian UH. In vivo imaging of lymphocyte trafficking. Ann Rev Cell Dev Biol 2005, 21:581-603.
23. Izzo AA, Borrelli F, Capasso R, Di Marzo V, Mechoulam R. Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci 2009, 30:515-527. 10.1016/j.tips.2009.07.006, 19729208.
24. Rajesh M, Mukhopadhyay P, Batkai S, Hasko G, Liaudet L, Drel VR, Obrosova IG, Pacher P. Cannabidiol attenuates high glucose-induced endothelial cell inflammatory response and barrier disruption. Am J Physiol Heart Circ Physiol 2007, 293:H610-H619. 10.1152/ajpheart.00236.2007, 2228254, 17384130.
25. Massi P, Valenti M, Vaccani A, Gasperi V, Perletti G, Marras E, Fezza F, Maccarrone M, Parolaro D. 5-Lipoxygenase and anandamide hydrolase (FAAH) mediate the antitumor activity of cannabidiol, a non-psychoactive cannabinoid. J Neurochem 2008, 104:1091-1100. 10.1111/j.1471-4159.2007.05073.x, 18028339.
26. Costa B, Colleoni M, Conti S, Parolaro D, Franke C, Trovato AE, Giagnoni G. Oral anti-inflammatory activity of cannabidiol, a non-psychoactive constituent of cannabis, in acute carrageenan-induced inflammation in the rat paw. Naun Schm Arch Pharmacol 2004, 369:294-299.
27. Pacher P, Batkai S, Kunos G. The endocannabinoid system as an emerging target of pharmacotherapy. Pharmacol Rev 2006, 58:389-462. 10.1124/pr.58.3.2, 2241751, 16968947.
28. Singh AK, Jiang Y. How does peripheral lipopolysaccharide induce gene expression in the brain of rats?. Toxicology 2004, 201:197-207. 10.1016/j.tox.2004.04.015, 15297033.
29. Villanueva A, Yilmaz MS, Millington WR, Cutrera RA, Stouffer DG, Parsons LH, Cheer JF, Feleder C. Central cannabinoid-1 receptor antagonist administration prevents endotoxic hypotension affecting norepinephrine release in the preoptic anterior hypothalamic area. Shock 2009, 32:614-620. 10.1097/SHK.0b013e3181a4fd8f, 19295473.
30. Alexander JJ, Jacob A, Cunningham, Hensley L, Quigg RJ. TNF is a key mediator of septic encephalopathy acting through its receptor, TNF receptor-1. Neurochem Intl 2008, 52:447-456.
31. Martínez-Orgado J, Fernández-López D, Moro MA, Lizasoain I. Nitric Oxide synthase as a target for the prevention of hypoxic-ischemic newborn brain damage. Curr Enzym Inhib 2006, 2:219-229.
32. Castillo AI, Tolón RM, Fernández-Ruiz JJ, Romero J, Martínez-Orgado J. The neuroprotective effect of cannabidiol in an in vitro model of newborn hypoxic-ischemic brain damage in mice is mediated by CB2 and adenosine receptors. Neurobiol Dis 2010, 37:434-440. 10.1016/j.nbd.2009.10.023, 19900555.
33. Esposito G, De Filippis D, Maiuri MC, De Stefano D, Carnuccio R, Iuvone T. Cannabidiol inhibits inducible nitric oxide synthase protein expression and nitric oxide production in beta-amyloid stimulated PC12 neurons through p38 MAP kinase and NF-kappaB involvement. Neurosci Lett 2006, 399:91-95. 10.1016/j.neulet.2006.01.047, 16490313.
34. Kozela E, Pietr M, Juknat A, Rimmerman N, Levy R, Vogel Z. Cannabinoids delta(9)-tetrahydrocannabinol and cannabidiol differentially inhibit the lipopolysaccharide-activated NF-kappaB and interferon-beta/STAT proinflammatory pathways in BV-2 microglial cells. J Biol Chem 285:1616-1626. 10.1074/jbc.M109.069294, 2804319, 19910459.
35. Pacher P, Beckman JS, Liaudet L. Nitric oxide and peroxynitrite in health and disease. Physiol Rev 2007, 87:315-424. 10.1152/physrev.00029.2006, 2248324, 17237348.
36. Sugaya K, Chou S, Xu SJ, McKinney M. Indicators of glial activation and brain oxidative stress after intraventricular infusion of endotoxin. Brain Res Mol Brain Res 1998, 58:1-9. 10.1016/S0169-328X(97)00365-3, 9685567.
37. Pertwee RG. The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: Δ9-tetrahydrocannabinol, cannabidiol and Δ9-tetrahydrocannabivarin. Br J Pharmacol 2008, 153:199-215. 10.1038/sj.bjp.0707442, 2219532, 17828291.
38. Kunos G, Jarai Z, Batkai S, Goparaju SK, Ishac EJ, Liu J, Wang L, Wagner JA. Endocannabinoids as cardiovascular modulators. Chem Phys Lipids 2000, 108:159-168. 10.1016/S0009-3084(00)00194-8, 11106789.
39. Tschöp J, Kasten KR, Nogueiras R, Goetzman HS, Cave CM, England LG, Dattilo J, Lentsch AB, Tschöp MH, Caldwell CC. The cannabinoid receptor 2 is critical for the host response to sepsis. J Immunol 2009, 183:499-505. 2763235, 19525393.
40. Lunn CA, Fine JS, Rojas-Triana A, Jackson JV, Fan X, Kung TT, Gonsiorek W, Schwarz MA, Lavey B, Kozlowski JA, Narula SK, Lundell DJ, Hipkin RW, Bober LA. A novel cannabinoid peripheral cannabinoid receptor-selective inverse agonist blocks leukocyte recruitment in vivo. J Pharmacol Exp Ther 2006, 316:780-788. 10.1124/jpet.105.093500, 16258021.
41. Walter L, Franklin A, Witting A, Wade C, Xie Y, Kunos G, Mackie K, Stella N. Nonpsychotropic cannabinoid receptors regulate microglial cell migration. J Neurosci 2003, 23:1398-1405.
42. Kozlowska H, Baranowska M, Schilcker E, Kozlowski M, Laudañski J, Malinowska B. Identification of the vasodilatory endothelial cannabinoid receptor in the human pulmonary artery. J Hypertens 2007, 25:2240-2248. 10.1097/HJH.0b013e3282ef7a0a, 17921818.
43. Kozlowska H, Baranowska M, Schilcker E, Kozlowski M, Laudañski J, Malinowska B. Virhodamine relaxes the human pulmonary artery through the endothelial cannabinoid receptor and indirectly through a COX product. Br J Pharmacol 2008, 155:1034-1042. 10.1038/bjp.2008.371, 2597267, 18806815.